Yes, marijuana is a controlled substance under federal law. It is classified as Schedule I under the Controlled Substances Act, the most restrictive category in the U.S. drug scheduling system. This means the federal government considers it to have a high potential for abuse, no currently accepted medical use, and no accepted safety for use under medical supervision. That classification puts marijuana in the same legal category as heroin and LSD, even though dozens of states have legalized it for medical or recreational use.
What Schedule I Means in Practice
The Controlled Substances Act organizes drugs into five schedules, with Schedule I being the most tightly restricted. For a substance to land in Schedule I, federal authorities must determine it meets all three criteria: high abuse potential, no accepted medical use in the U.S., and a lack of accepted safety even under medical supervision. Both the DEA and the FDA have maintained that marijuana meets these criteria at the federal level.
Because of this classification, it is illegal under federal law to produce, dispense, or possess marijuana except in the context of federally approved scientific studies. This is true regardless of what any state law says. The practical result is a legal gray zone where a cannabis dispensary can operate legally under state law while technically violating federal law every day it’s open.
How Federal and State Laws Conflict
The gap between federal and state marijuana law is one of the most unusual situations in American law. As of 2024, the majority of states have legalized marijuana in some form, whether for medical use, recreational use, or both. Yet every one of those state programs exists in tension with the Controlled Substances Act.
The federal government has generally chosen not to prosecute individuals or businesses that comply with strong state regulatory systems. A 2013 Department of Justice memo outlined federal enforcement priorities, directing prosecutors to focus on specific harms rather than broadly targeting state-legal activity. Those priorities include preventing distribution to minors, keeping marijuana revenue away from cartels and gangs, stopping diversion of marijuana to states where it remains illegal, and preventing violence in the cannabis trade. The memo made clear that conduct in compliance with robust state laws “is less likely to threaten the federal priorities.” But it also warned that if a state’s enforcement proves too weak, the federal government could challenge the entire regulatory structure.
This enforcement approach is a matter of policy, not law. It can change with any new administration, which creates ongoing uncertainty for cannabis businesses and consumers in legal states.
The Hemp Exception
Not all cannabis is treated as a controlled substance. The 2018 Farm Bill carved out a legal distinction between marijuana and hemp based on one molecule: delta-9 THC. Hemp is defined as any part of the cannabis plant containing no more than 0.3% delta-9 THC on a dry-weight basis. Anything above that threshold is marijuana under federal law and remains a Schedule I controlled substance. Anything at or below it is legal hemp, which can be grown, processed, and sold commercially.
This 0.3% line has created its own set of complications. Products derived from hemp, including certain THC-containing edibles and beverages, have flooded the market in a regulatory gray area. They are technically legal under the Farm Bill’s definition, but the distinction between a “hemp product” and a “marijuana product” often comes down to a fraction of a percentage point of THC content.
How Schedule I Status Affects Research
Marijuana’s Schedule I classification creates significant barriers for scientists trying to study it. Researchers who want to work directly with cannabis containing more than 0.3% THC must obtain a special Schedule I research registration from the DEA. Federally funded researchers cannot use any funds to obtain cannabis from state dispensaries, even in states where it’s legal. No state dispensary has been approved by the DEA to supply cannabis for research purposes.
The restrictions shape what kinds of studies are even possible. Researchers using federal funding can conduct observational studies, collect self-reported data on cannabis use, and gather biological samples from people who use cannabis on their own. But they cannot distribute cannabis products to study participants or allow consumption in federally funded facilities. This means that while millions of Americans use marijuana daily, the scientific infrastructure to rigorously study its effects, benefits, and risks remains constrained by the same scheduling that classifies it alongside the most dangerous drugs.
The Tax Burden on Cannabis Businesses
Schedule I status hits cannabis businesses in a place that might not be obvious: their tax returns. Section 280E of the Internal Revenue Code prohibits any business trafficking in Schedule I or Schedule II controlled substances from claiming standard tax deductions or credits. For a cannabis company, this means expenses that any other business would deduct, such as rent, employee wages, marketing, and utilities, are not deductible. The result is that legal cannabis businesses often pay effective tax rates far higher than businesses in other industries, sometimes exceeding 70%.
The banking situation compounds this. Because marijuana remains federally illegal, financial institutions that handle cannabis proceeds risk violating anti-money laundering laws. Many banks and credit unions simply refuse to work with cannabis businesses. Legislation like the proposed SAFE Banking Act has attempted to shield financial institutions from federal penalties for serving state-legal cannabis companies, but has not yet passed. This leaves many cannabis businesses operating largely in cash, which creates security risks and operational headaches.
The Push to Reschedule
The federal government has taken concrete steps toward moving marijuana from Schedule I to Schedule III. In May 2024, the Department of Justice published a formal notice of proposed rulemaking to reschedule marijuana. The DEA began administrative hearings on the proposal in January 2025, with proceedings scheduled through early March 2025. The process involves weeks of testimony and evidence review, and a final decision could take months or longer after hearings conclude.
Moving marijuana to Schedule III would not legalize it. It would still be a controlled substance, but the practical implications would shift substantially. Schedule III substances are recognized as having accepted medical uses and a lower potential for abuse than Schedule I or II drugs. The reclassification would lift the Section 280E tax penalty, allowing cannabis businesses to deduct normal business expenses for the first time. It would also ease some research restrictions, though scientists would still need DEA registration to work with the substance.
What rescheduling would not do is resolve the conflict between federal and state law. State recreational marijuana programs would still lack federal authorization. Possession without a prescription would still be a federal offense. And the patchwork of state laws, from full legalization to complete prohibition, would remain as complicated as ever.
International Treaty Obligations
The U.S. isn’t making these decisions in a vacuum. The 1961 Single Convention on Narcotic Drugs, a United Nations treaty that the U.S. signed, requires member nations to limit cannabis production and use “exclusively to medical and scientific purposes.” Cannabis was originally placed in the Convention’s most restrictive schedule, which recommended prohibiting even medical use. That placement reflected the influence of a group of control advocates who held sway at the UN during the late 1940s and 1950s and pushed an aggressive anti-narcotics agenda.
The treaty creates a floor for how far the U.S. can go in loosening marijuana restrictions without either renegotiating international agreements or withdrawing from them. Full descheduling, removing marijuana from the Controlled Substances Act entirely, would be difficult to reconcile with these treaty obligations. Rescheduling to Schedule III, on the other hand, aligns more easily with the Convention’s allowance for medical and scientific use.